Sun Pharma announced Thursday morning that it is acquiring Concert Pharmaceuticals for $576 million. The Indian-based pharma company will acquire all outstanding shares of the late-stage biotech that ...

As Concert Pharmaceuticals prepares for an FDA submission for its experimental treatment for hair loss, it has also been exploring potential partnerships to help sell the drug in the U.S. But instead ...

Please provide your email address to receive an email when new articles are posted on . Sun Pharma has reached a definitive agreement to acquire outstanding shares of Concert Pharmaceuticals Inc. for ...

Concert Pharmaceuticals and members of its board of directors were hit with a securities lawsuit on Monday in New York Southern District Court over the company's proposed acquisition by Sun Pharma for ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a request for additional information (“Second Request”) from the United States ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min An Indian drugmaker will buy ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. A Lexington company that aims to improve upon approved or ...

Shares of Concert Pharmaceuticals, Inc. CNCE were up 17.4% last week on its proposed acquisition by India-based Sun Pharmaceutical Industries Ltd. On Jan 19, Concert Pharmaceuticals announced a ...

Concert Pharmaceuticals Inc. is on track for an NDA filing for CTP-543 in alopecia areata during the first half of 2023, following a positive read-out from the first of two phase III trials of the ...

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and ...